TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01959438
Drug: Sodium selenite
Normalized name: Sodium selenite
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous treatment as described above. Cohorts of 3 patient are given a fixed dose for daily treatment (started with 0.5 mg/m2) and if no grade 3 or 4 toxicity, a new cohort is started on a higher dose. The dose for next cohort is 50% higher than for the former cohort. If grade 3 or 4 toxicity is found in 1 patient, 3 more patients are included on the same dose and if one more patient has serious toxicity it is considered to high a dose and a dose in between the toxic dose and the one before is tested. Thus if 2 patients in 3-6 tested patients has serious toxicity by a certain dose, this dose is to high and the highest dose is considered the earlier tested dose.
Study: NCT03834233
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
Study: NCT01762150
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400mg BID by oral until progressed;
Study: NCT03212807
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Investigational Medicinal Product
Study: NCT01762150
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine: 1000mg/m2, administered by intravenous drip for 30\~60min on Day 1 and 8,for 4 cycles;
Study: NCT01762150
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin: 25mg/m2, administered by intravenous drip on Day 1-3, with appropriate liquid hydration,for 4 cycles.
Study: NCT02710448
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (Glucophage ®), oral antidiabetic, will be administered as it is usually recommended: engaged during or at the end of the meal in the evening for the single dose 500 mg (Phase 1), the evening and morning for total doses of 1000 mg, 2000 mg and 3000 mg (with, respectively, 2 tab. 500 mg, 2 tab. to 1000 mg, 1 tab. to 1000 mg and 2 tab. to 1000 mg), a fourth dose is also scheduled to stage one (3000 mg / d)
Study: NCT00059644
Drug: Ecraprost in lipid emulsion
Normalized name: propofol lipid emulsion
DrugBank: Ecraprost (DB16148)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00349206
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT03212807
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Investigational Medicinal Product
Study: NCT00223288
Drug: Lexapro
Normalized name: Lexapro
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02249026
Drug: BZDs + opiate exposure treated with BPN
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: These infants will have been exposed not only to opiates but also to BZDs during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
Study: NCT02249026
Drug: Opiates exposure treated with BPN
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: These infants will have been exposed not only to opiates during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
Study: NCT01376245
Drug: fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhaled corticosteroid/long acting beta-agonist
Study: NCT00349206
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00422890
Drug: 5-Azacytidin
Normalized name: 5-azacytidine
DrugBank: 5,6-dihydro-5-azacytidine (DB17151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: in case of decreasing CD34 chimerism
Study: NCT00050960
Drug: bexarotene with carboplatin and paclitaxel
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: bexarotene capsules (400 mg/m\^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.
Study: NCT00050960
Drug: carboplatin and paclitaxel
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks.
Study: NCT00415610
Drug: nicardipine
Normalized name: Nicardipine
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.~* Started at 5mg/h~* Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour \*Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued.
Study: NCT01143688
Drug: albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04275960
Drug: Selitrectinib (BAY2731954)
Normalized name: entrectinib
DrugBank: Selitrectinib (DB14896)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Selitrectinib is administered orally as liquid suspension (20 mg/mL) on Day 1 of each period. Each period lasts 4 days, both periods of each arm are separated by at least 3 days.
Study: NCT00702728
Drug: Furosemide and matched saline hydration
Normalized name: furosemide and potassium
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will begin treatment approximately 90 minutes prior to the start of catheterization procedure. After a pre-hydration bolus of 250 ml of normal saline solution over 30 minutes the patient will receive 0.5 mg/kg of furosemide intravenously. Then, a replacement solution (saline) is given in an amount matched (ml for ml) to the volume of urine produced. Matched hydration will occur prior, during, and 4 hours post procedure.
Study: NCT02820441
Drug: Zopiclone
Normalized name: zopiclone
DrugBank: Zopiclone (DB01198)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01957163
Drug: FF
Normalized name: MFF
DrugBank: Melphalan flufenamide (DB16627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
Study: NCT01957163
Drug: VI
Normalized name: VIG
DrugBank: Human vaccinia virus immune globulin (DB14112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
Study: NCT01418274
Drug: danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral doses of danoprevir
Study: NCT01418274
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral doses of escitalopram
Study: NCT01418274
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral doses of ritonavir
Study: NCT01957163
Drug: UMEC
Normalized name: Umecta
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
Study: NCT01248364
Drug: BI 10773
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 10773 tablets once daily high dose
Study: NCT01686789
Drug: Pegylated interferon alpha-2a
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03026023
Drug: Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HCV treatment for 12 to 16 weeks. Treatment length and addition of ribavirin based upon presence of baseline resistance associated variant in the HCV virus. Medications given concurrently.
Study: NCT03196869
Drug: cisplatin chrono-chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental group: cisplatin chrono-chemotherapy
Study: NCT03196869
Drug: cisplatin routine-chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: control group:cisplatin routine-chemotherapy
Study: NCT01169714
Drug: 0.1 mg PF-04995274
DrugBank: PF-04995274 (DB12675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg PF-04995274, qd, for 14 days or placebo
Study: NCT01169714
Drug: 1 mg PF-04995274
Normalized name: fluorouracil
DrugBank: PF-04995274 (DB12675)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg PF-04995274, qd, for 14 days or placebo
Study: NCT01169714
Drug: 10 mg PF-04995274
Normalized name: threonine
DrugBank: PF-04995274 (DB12675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg PF-04995274, qd, for 14 days or placebo
Study: NCT01169714
Drug: 15 mg PF-04995274
Normalized name: PF-04995274
DrugBank: PF-04995274 (DB12675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg PF-04995274, qd, for 14 days or placebo
Study: NCT01873170
Drug: levonorgestrel exposure
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01873170
Drug: DMPA exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01873170
Drug: etonogestrel exposure
Normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03243006
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 tablets of 500mg of paracetamol
Study: NCT03243006
Drug: Tramadol/Paracetamol combination
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 tablets of tramadol/paracetamol combination (32.5mg/325mg)
Study: NCT01054859
Drug: avanafil
Normalized name: Avanafil
DrugBank: Avanafil (DB06237)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200 mg avanafil tablet QD plus 0.5 g/kg alcohol
Study: NCT00430248
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.
Study: NCT00430248
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
Study: NCT00430248
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months.~Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily.
Study: NCT01054859
Drug: avanafil
Normalized name: Avanafil
DrugBank: Avanafil (DB06237)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200 mg avanafil tablet QD
Study: NCT00380250
Drug: Lubiprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01158235
Drug: LTX-109
Normalized name: LTX-109
DrugBank: LTX-109 (DB12711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1%, 2% and 3% Lytixar (gel formulation). TID for 3 days.
Study: NCT01262456
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02486289
Drug: Emeramide
Normalized name: Emeramide
DrugBank: Emeramide (DB12192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)
Study: NCT04466137
Drug: YPEG-rhG-CSF
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: YPEG-rhG-CSF 2mg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
Study: NCT01301391
Drug: Milciclib Maleate
Normalized name: Milciclib Maleate
DrugBank: Milciclib Maleate (DB16232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity.
Study: NCT04466137
Drug: YPEG-rhG-CSF
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: YPEG-rhG-CSF 33μg/kg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
Study: NCT01920126
Drug: sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mmol/kg for 1 hr, and then 0.15 mmol/kg/h for 23 hrs The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
Study: NCT01920126
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02466958
Drug: levomilnacipran
Normalized name: Levomilnacipran
DrugBank: Levomilnacipran (DB08918)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antidepressant
Study: NCT00000520
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02629991
Drug: Intranasal Oxytocin (IN-OXT)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
Study: NCT02133599
Drug: IOHEXOL
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive 5 mL of Iohexol prior to cycle 1 and 4 of HDMTX
Study: NCT00466635
Drug: GT267-004 (tolevamer potassium sodium)
Normalized name: potassium bitartrate 0.004 MG/MG
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02235246
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: magnesium sulfate 50 mg/kg will be administrated during 10 min before anesthetic induction in patients undergoing endoscopic submucosal dissection.
Study: NCT00049374
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00049374
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02047500
Drug: TH-302
Normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Study: NCT02047500
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel will be administered at a dose ranging from 100-125 mg/m\^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Study: NCT02047500
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered at a dose ranging from 800-1000 mg/m\^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Study: NCT00330174
Drug: Acamprosate
Normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 333mg tablets three times daily
Study: NCT01520818
Drug: biphasic insulin aspart 50
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m\^2 will receive BIAsp 50
Study: NCT02091752
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to \<200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
Study: NCT01520818
Drug: biphasic insulin aspart 70
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m\^2 will receive BIAsp 70
Study: NCT01520818
Drug: biphasic human insulin 30
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin), twice a day
Study: NCT03332303
Drug: Estradiol Vaginal Cream
Normalized name: Estradiol Vaginal Cream
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol Vaginal Cream
Study: NCT03985891
Drug: Anti-PD-1 Monoclonal Antibody JS001
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 monoclonal antibody combined with chemotherapy in patients with locally advanced colon cancer (perioperative treatment)
Study: NCT00546780
Drug: Tanespimycin
Normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion
Study: NCT00546780
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus
Study: NCT03776760
Drug: sofosbuvir/velpatesvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
Study: NCT03776760
Drug: glecaprevir/pibrentasvir
Normalized name: GLECAPREVIR/PIBRENTASVIR
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
Study: NCT01595893
Drug: Oral Vitamin D 3
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40,000 IE vitamin D3 per 70 kg body weight, given twice (2 weeks apart)
Study: NCT01595893
Drug: Miglyol 812 N
Normalized name: N-Vanillylnonamide
DrugBank: Nonivamide (DB11324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral oil of esters extracted from coconut and palm kernel
Study: NCT03156738
Drug: MT-2990
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single IV dose of MT-2990
Study: NCT01287130
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day 1 administer cetuximab 400 mg/m2 IV loading dose over 120 minutes. On days 8, 15 and 22 administer cetuximab 250 mg/m2 IV loading dose over 60 minutes
Study: NCT03399643
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab is administered via IV 1200 mg every 3 weeks
Study: NCT03865004
Drug: Paracetamol+Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1gr paracetamol plus 0.1 mg/kg morphine were performed simultanously
Study: NCT03888664
Drug: gamma interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st two weeks: gIFN 100 ugr/three times a week from the 3rd week: gIFN 200 ugr/ three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
Study: NCT01080222
Drug: telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: tablet, 1125-mg, twice daily
Study: NCT03865004
Drug: Placebo plus Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 cc NaCl plus 0.1 mg/kg morphine were performed simultanously
Study: NCT02131922
Drug: Chlorhexidine (Intensive Treatment)
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (PerioKIN) (0.2%) implantation in dental pockets